Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mithramycin 24h Infusion in Thoracic Malignancies
NCT02859415Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Mithramycin in lung cancer, esophageal cancer, malignant pleural mesothelioma (MPM), Thymic Neoplasms (TN), germ cell tumor (GCT), sponsored by National Cancer Institute. Started Aug 2019; status: terminated.
02
Drugs
Mithramycin
03
Conditions
lung canceresophageal cancermalignant pleural mesothelioma (MPM)Thymic Neoplasms (TN)germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT02859415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859415.